Paige, a global leader in end-to-end digital pathology solutions and clinical artificial intelligence (AI) solutions to assist cancer diagnosis, has entered into a partnership with Visiopharm an AI-driven precision pathology software provider, with the aim of bringing a wider range of AI pathology solutions to healthcare professionals and patients.
The partnership will see VisioPharm’s AI application deployed and integrated into the Paige Platform, to be accessed through Paige’s AI clinical worklist, FullFolio, and viewed with FullFocus, Paige’s whole-slide image viewer. The integration will allow users reviewing IHC-stained slides greater diagnostic efficiency and quality insights, as well as improving the user experience for Visiopharm’s image analysis applications, helping pathologists to deliver faster and more accurate diagnosis.
Dr. Michael Grunkin, CEO of Visiopharm, stated, "Visiopharm, a global leader in AI-driven precision pathology, delivers standardized decision support for complex tissue biomarkers. Our fully automated (zero-click) applications use a cascade of deep learning networks for slide quality control, tissue detection, tumor identification, and biomarker quantification. Designed to work across various technologies and providers, we join Paige in our commitment to making this technology accessible worldwide on top pathology platforms."
Click here to read the original news story.